Ciprofibrate therapy improves endothelial function and reduces postprandial lipemia and oxidative stress in type 2 diabetes mellitus

Marc Evans; Richard A. Anderson; John Graham; Gethin R. Ellis; Keith Morris; Stephen Davies; Simon K. Jackson; Malcolm J. Lewis; Michael P. Frenneaux; Alan Rees

doi:10.1161/01.CIR.101.15.1773

Ciprofibrate therapy improves endothelial function and reduces postprandial lipemia and oxidative stress in type 2 diabetes mellitus

Marc Evans, Richard A. Anderson, John Graham, Gethin R. Ellis, Keith Morris, Stephen Davies, Simon K. Jackson, Malcolm J. Lewis, Michael P. Frenneaux, Alan Rees

Research output: Contribution to journal › Article › peer-review

212 Citations (Scopus)

Abstract

Exaggerated postprandial lipemia (PPL) is a factor in atherogenesis, involving endothelial dysfunction and enhanced oxidative stress. We examined the effect of ciprofibrate therapy on these parameters in type 2 diabetes mellitus.

Original language	English
Pages (from-to)	1773-1779
Number of pages	7
Journal	Circulation
Volume	101
Issue number	15
DOIs	https://doi.org/10.1161/01.CIR.101.15.1773
Publication status	Published - 18 Apr 2000

Keywords

Adult
Analysis of Variance
Area Under Curve
Cholesterol, HDL
Clofibric Acid
Diabetes Mellitus, Type 2
Double-Blind Method
Endothelium, Vascular
Female
Fibric Acids
Humans
Hypolipidemic Agents
Lipids
Male
Middle Aged
Oxidative Stress
Postprandial Period
Triglycerides

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1161/01.CIR.101.15.1773

Cite this

@article{c4c9643019254b7a9bd3f68f91670bda,

title = "Ciprofibrate therapy improves endothelial function and reduces postprandial lipemia and oxidative stress in type 2 diabetes mellitus",

abstract = "Exaggerated postprandial lipemia (PPL) is a factor in atherogenesis, involving endothelial dysfunction and enhanced oxidative stress. We examined the effect of ciprofibrate therapy on these parameters in type 2 diabetes mellitus.",

keywords = "Adult, Analysis of Variance, Area Under Curve, Cholesterol, HDL, Clofibric Acid, Diabetes Mellitus, Type 2, Double-Blind Method, Endothelium, Vascular, Female, Fibric Acids, Humans, Hypolipidemic Agents, Lipids, Male, Middle Aged, Oxidative Stress, Postprandial Period, Triglycerides",

author = "Marc Evans and Anderson, {Richard A.} and John Graham and Ellis, {Gethin R.} and Keith Morris and Stephen Davies and Jackson, {Simon K.} and Lewis, {Malcolm J.} and Frenneaux, {Michael P.} and Alan Rees",

year = "2000",

month = apr,

day = "18",

doi = "10.1161/01.CIR.101.15.1773",

language = "English",

volume = "101",

pages = "1773--1779",

journal = "Circulation",

issn = "0009-7322",

publisher = "Lippincott, Williams and Wilkins",

number = "15",

}

TY - JOUR

T1 - Ciprofibrate therapy improves endothelial function and reduces postprandial lipemia and oxidative stress in type 2 diabetes mellitus

AU - Evans, Marc

AU - Anderson, Richard A.

AU - Graham, John

AU - Ellis, Gethin R.

AU - Morris, Keith

AU - Davies, Stephen

AU - Jackson, Simon K.

AU - Lewis, Malcolm J.

AU - Frenneaux, Michael P.

AU - Rees, Alan

PY - 2000/4/18

Y1 - 2000/4/18

N2 - Exaggerated postprandial lipemia (PPL) is a factor in atherogenesis, involving endothelial dysfunction and enhanced oxidative stress. We examined the effect of ciprofibrate therapy on these parameters in type 2 diabetes mellitus.

AB - Exaggerated postprandial lipemia (PPL) is a factor in atherogenesis, involving endothelial dysfunction and enhanced oxidative stress. We examined the effect of ciprofibrate therapy on these parameters in type 2 diabetes mellitus.

KW - Adult

KW - Analysis of Variance

KW - Area Under Curve

KW - Cholesterol, HDL

KW - Clofibric Acid

KW - Diabetes Mellitus, Type 2

KW - Double-Blind Method

KW - Endothelium, Vascular

KW - Female

KW - Fibric Acids

KW - Humans

KW - Hypolipidemic Agents

KW - Lipids

KW - Male

KW - Middle Aged

KW - Oxidative Stress

KW - Postprandial Period

KW - Triglycerides

U2 - 10.1161/01.CIR.101.15.1773

DO - 10.1161/01.CIR.101.15.1773

M3 - Article

C2 - 10769276

VL - 101

SP - 1773

EP - 1779

JO - Circulation

JF - Circulation

SN - 0009-7322

IS - 15

ER -